Diverse trends in antihypertensive medication usage among U.S. Adults with hypertension by socioeconomic status and comorbidities, 1999-2020.

IF 2.3 4区医学

Blood Pressure Pub Date : 2025-12-01 Epub Date: 2025-05-21 DOI:10.1080/08037051.2025.2506081

Junwen Wang, Yuyang Ye, Xuefeng Chen, Xinru Hu, Yong Peng

{"title":"Diverse trends in antihypertensive medication usage among U.S. Adults with hypertension by socioeconomic status and comorbidities, 1999-2020.","authors":"Junwen Wang, Yuyang Ye, Xuefeng Chen, Xinru Hu, Yong Peng","doi":"10.1080/08037051.2025.2506081","DOIUrl":null,"url":null,"abstract":"Background: Hypertension is a global health concern, and antihypertensive medications are vital for its management. This study examined evolving trends in antihypertensive medication usage among adults with hypertension from 1999 to 2020.Methods: Data from 10 National Health and Nutrition Examination Survey (NHANES) survey cycles were obtained for adults aged 18 years and older with hypertension. The study analysed demographic, drug classification and demographic variables. All statistical analyses, including logistic regression, were used to assess trends.Results: Among 18,221 hypertensive participants, diverse characteristics were observed. The use of angiotensin-converting enzyme inhibitors increased from 26.18% in 1999 to 32.76% in 2020 (linear p = 0.001). Angiotensin receptor blocker use rose from 10.36% to 26.57%. Beta blocker usage increased from 28.98% in 1999 to 42.50% in 2010, plateauing at approximately 40% from 2011 to 2020 (quadratic p < 0.001). Calcium channel blocker (CCB) utilisation increased from 16.70% in 1999 to 20.46% in 2020 (linear p < 0.001). Diuretic (DU) use decreased from 32.70% in 1999 to 26.34% in 2020 (quadratic p = 0.009). The use of antihypertensive medications varies across different demographic groups and comorbidities.Conclusions: ACEI, ARB and CCB usage increased, while DU usage decreased. BB utilisation stabilised at a high rate. Antihypertensive drug use displayed diverse trends across demographic groups and comorbidities.","PeriodicalId":9000,"journal":{"name":"Blood Pressure","volume":" ","pages":"2506081"},"PeriodicalIF":2.3000,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Blood Pressure","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/08037051.2025.2506081","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/5/21 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Hypertension is a global health concern, and antihypertensive medications are vital for its management. This study examined evolving trends in antihypertensive medication usage among adults with hypertension from 1999 to 2020.

Methods: Data from 10 National Health and Nutrition Examination Survey (NHANES) survey cycles were obtained for adults aged 18 years and older with hypertension. The study analysed demographic, drug classification and demographic variables. All statistical analyses, including logistic regression, were used to assess trends.

Results: Among 18,221 hypertensive participants, diverse characteristics were observed. The use of angiotensin-converting enzyme inhibitors increased from 26.18% in 1999 to 32.76% in 2020 (linear p = 0.001). Angiotensin receptor blocker use rose from 10.36% to 26.57%. Beta blocker usage increased from 28.98% in 1999 to 42.50% in 2010, plateauing at approximately 40% from 2011 to 2020 (quadratic p < 0.001). Calcium channel blocker (CCB) utilisation increased from 16.70% in 1999 to 20.46% in 2020 (linear p < 0.001). Diuretic (DU) use decreased from 32.70% in 1999 to 26.34% in 2020 (quadratic p = 0.009). The use of antihypertensive medications varies across different demographic groups and comorbidities.

Conclusions: ACEI, ARB and CCB usage increased, while DU usage decreased. BB utilisation stabilised at a high rate. Antihypertensive drug use displayed diverse trends across demographic groups and comorbidities.

查看原文本刊更多论文

1999-2020年美国成人高血压患者抗高血压药物使用的社会经济状况和合并症的不同趋势

背景：高血压是一个全球性的健康问题，抗高血压药物对其治疗至关重要。本研究调查了1999年至2020年成人高血压患者抗高血压药物使用的演变趋势。方法：采用全国健康与营养调查（NHANES）对18岁及以上高血压患者的10个调查周期的数据。该研究分析了人口统计学、药物分类和人口统计学变量。所有的统计分析，包括逻辑回归，都被用来评估趋势。结果：在18221名高血压患者中，观察到多种特征。血管紧张素转换酶抑制剂的使用从1999年的26.18%增加到2020年的32.76%（线性P = 0.001）。血管紧张素受体阻滞剂的使用率从10.36%上升到26.57%。β受体阻滞剂的使用率从1999年的28.98%上升到2010年的42.50%，从2011年到2020年稳定在约40%（二次P < 0.001）。钙通道阻滞剂利用率从1999年的16.70%上升到2020年的20.46%（线性P < 0.001）。利尿剂使用率由1999年的32.70%下降到2020年的26.34%（二次P = 0.009）。抗高血压药物的使用在不同的人口群体和合并症中有所不同。结论：ACEI、ARB、CCB使用率上升，DU使用率下降。BB利用率稳定在较高水平。抗高血压药物的使用在不同的人口群体和合并症中表现出不同的趋势。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Blood Pressure Medicine-Cardiology and Cardiovascular Medicine

CiteScore

3.20

自引率

5.60%

发文量

期刊介绍： For outstanding coverage of the latest advances in hypertension research, turn to Blood Pressure, a primary source for authoritative and timely information on all aspects of hypertension research and management. Features include: • Physiology and pathophysiology of blood pressure regulation • Primary and secondary hypertension • Cerebrovascular and cardiovascular complications of hypertension • Detection, treatment and follow-up of hypertension • Non pharmacological and pharmacological management • Large outcome trials in hypertension.